Eloxx Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Eloxx Pharmaceuticals, Inc. - overview
Established
2013
Location
Watertown, MA, US
Primary Industry
Pharmaceuticals
About
Eloxx Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing innovative ribosome-targeted genetic therapies to address genetic defects associated with rare diseases and cancers. Founded in 2013 in Watertown, US, Eloxx Pharmaceuticals focuses on developing therapies targeting nonsense mutations and ribosomal mutations related to various genetic disorders and cancers. The company has undergone significant funding rounds, with its latest notable fundraising of USD 15.
90 mn in a GRANT led by the Cystic Fibrosis Foundation. Eloxx has raised a total of USD 30. 00 mn to date. Eloxx Pharmaceuticals specializes in developing ribosome-targeted genetic therapies aimed at correcting genetic defects associated with rare diseases and cancer.
Their lead product, TURBO-ZM™, enhances mRNA translation to restore proper protein synthesis and function. These therapies target patients suffering from genetic diseases and malignancies, and Eloxx's products are marketed in North America and Europe to healthcare providers, specialty pharmacies, and research institutions. In the most recent financial year of 2016, Eloxx Pharmaceuticals reported a revenue of USD 75,000, while the EBITDA for the same year was reported at USD -33,183,000. Eloxx Pharmaceuticals plans to utilize its most recent funding of USD 15.
90 mn to further develop its platform technology and upcoming product launches. The company aims to expand its market presence, particularly targeting additional regions in North America and Europe by the end of 2023. Recent funding will support these initiatives, following the completion of an IPO in April 2018 that raised USD 50. 02 mn, highlighting the company's ongoing commitment to advancing its innovative therapies.
Current Investors
Pontifax Venture Capital, Korea Investment Partners, DSC Investment
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Diagnostic, Medical & Imaging Laboratories, Pharmaceutical Research & Development
Website
www.eloxxpharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Eloxx Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Jun 30, 2013 | Jun 30, 2014 | Jun 30, 2015 | Jun 30, 2016 | Jun 30, 2017 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 100,000 | 75,000 | 75,000 | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | (25.0%) | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (4,356,871) | (8,798,140) | (17,899,662) | (11,101,589) | (4,548,794) | (19,683,000) | (47,349,000) | (49,762,000) | (32,306,000) | (64,638,000) | (33,183,000) | - | - | - |
| Operating Income (USD) | (4,650,500) | (9,147,796) | (18,076,736) | (11,194,983) | (4,592,869) | (20,390,000) | (47,565,000) | (50,555,000) | (33,455,000) | (66,018,000) | (34,419,000) | - | - | - |
| Operating Margin | - | (9147.8%) | (24102.3%) | (14926.6%) | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | (8798.1%) | (23866.2%) | (14802.1%) | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (6,122,542) | (9,225,234) | (18,063,785) | (8,267,929) | (5,796,363) | (21,214,000) | (47,185,000) | (50,874,000) | (34,577,000) | (66,727,000) | (36,065,000) | - | - | - |
| % Net Margin | - | (9225.2%) | (24085.0%) | (11023.9%) | - | - | - | - | - | - | - | - | - | - |
Eloxx Pharmaceuticals, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.